ClinicalTrials.gg
CompletedNCT00536666Updated Oct 8, 2008

A Study of Iron Oligosaccharide in Chronic Kidney Disease Patients

A Phase 3 interventional study of Iron oligosaccharide in Chronic Kidney Disease and Anemia, Iron-Deficiency, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-08.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
182
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 116 studies in Renal Insufficiency, Chronic with a site in Denmark — 27 open to participants now, 35 under way, 9 of them phase 3. Renal Insufficiency, Chronic · Denmark.

Enrollment
39th of 90
182 · median 136
Started
2007
with 3 others
Phase 3
31 of 116
4 open now
Registered
9th of 116
by date

Among the 116 studies in Renal Insufficiency, Chronic with a site in Denmark, this one is the 39th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2007, is one of 31 in phase 3, and was the 9th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

27 of the 116 studies in Renal Insufficiency, Chronic with a site in Denmark are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 116 studies in Renal Insufficiency, Chronic with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety profile of iron oligosaccharide in patients with chronic kidney disease with a need for parenteral iron.

Read the detailed description

Iron dextrans have been marketed for more than 50 years and the compiled preclinical and clinical experience with iron dextrans in general is well established. Pharmacosmos A/S already markets the iron dextran CosmoFer® worldwide, except in the US where the product is named INFeD®. A new iron oligosaccharide has been manufactured by Pharmacosmos A/S and it is a further development of CosmoFer® where ferric hydroxide has been combined with low molecular weight oligosaccharides in a relatively strong complex. This iron carbohydrate complex builds on the well established efficacy and safety profile of existing iron dextran but with a significantly reduced anaphylactic potential.

In order to ensure that iron oligosaccharide will not lead to unexpected adverse events the existing clinical information on iron dextrans in general needs to be supplied with clinical safety data from a limited number of relevant patients exposed to iron oligosaccharide in open label non-comparator studies.

The primary objective of the present study is to obtain such safety reassurance with the use of iron oligosaccharide given either as repeated IV boluses or as total dose infusion for correction/maintenance therapy of anaemia in patients with chronic kidney disease with a need for parenteral iron due to either absolute or functional iron deficiency anaemia.

03

Conditions studied

  • Chronic Kidney Disease
  • Anemia, Iron-Deficiency

Keywords

  • Chronic kidney disease
  • Aneamia
  • Iron oligosaccharide
  • Chronic kidney disease patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Chronic kidney disease patients in pre-dialysis or undergoing dialysis not currently treated with parenteral iron may be included if they meet the following criteria:

  • ≥ 18 years of age at screening
  • \< 110 g/L (6.8 mmol/L)
  • Serum ferritin \< 800 µgram/L
  • beyond 12 months
  • Willingness to participate after written

Chronic kidney disease patients in pre-dialysis or undergoing dialysis willing to switch their current parenteral iron maintenance therapy to iron oligosaccharide may be included if they meet the following criteria:

  • ≥ 18 years of age at screening
  • Hb ≤ 130 g/L
  • Serum ferritin > 200 µgram/L but \< 800 µgram/L
  • Life expectancy beyond 12 months
  • Willingness to participate after written informed consent

Exclusion criteria

Exclusion Criteria:

  • Non iron deficiency anaemia
  • Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis, haemosiderosis)
  • Drug (i.e. previous hypersensitivity to iron dextran or iron mono- or disaccharide complexes)
  • Patients with a history of multiple allergies.
  • Decompensated liver cirrhosis and hepatitis ( > 3 times normal).
  • Acute or chronic infections
  • Rheumatoid arthritis with symptoms or signs of active inflammation
  • Pregnancy and nursing. To avoid pregnancy, women have to be , surgically sterile, sexually inactive or practice reliable
  • Active bleeding
  • Planned elective surgery during the study where significant blood loss is expected
  • Participation in any other clinical trial within three months prior to screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
182 participants (actual)

Study arms

  • Other
    1

    Iron oligosaccharide

    Drug: Iron oligosaccharide

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events (AE) (Number and type of AE)

    Time frame: Eight weeks after enrollment

  2. Serious adverse events (SAEs)

    Time frame: Eight weeks after enrollment

  3. Physical examination

    Time frame: At screening visit and at end of study

  4. Vital signs

    Time frame: At every visit

  5. Clinical laboratory tests (biochemistry, haematology)

    Time frame: At every visit

Secondary outcomes

  1. Change from baseline in haemoglobin, haematocrit, s-iron, transferrin saturation, and ferritin levels

    Time frame: At every visit

07

Study locations

1 site
  • Rigshospitalet, Nefrologisk afdeling P
    Copenhagen, DK-2100, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2007
First posted
Sep 28, 2007
Start
May 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Last update
Oct 8, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00536666
Lead sponsor
Pharmacosmos A/S
First posted
Sep 28, 2007
Start date
May 2007
Primary completion
Aug 2008
Completion
Aug 2008
Last update
Oct 8, 2008

Study contacts

Soeren Ladefoged, MD, DMSc
principal investigator · Rigshospitalet, Nefrologisk afdeling P

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion